Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)
| 193.71 Delayed Data As of Jun 02 |  +5.04 / +2.67%Today’s Change | 120.43 Today|||52-Week Range 242.97 | -18.49% Year-to-Date |
Latest ALNY News | Press Releases
| Alnylam (ALNY) Reports Positive Results From APOLLO-B Study May 22 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 188.67 |
| Today’s open | 190.61 |
| Day’s range | 188.88 - 195.75 |
| Volume | 11,452 |
| Average volume (3 months) | 773,426 |
| Market cap | $24.1B |
Data as of 4:00pm ET, 06/02/2023
Growth & Valuation
| Earnings growth (last year) | -29.11% |
| Earnings growth (this year) | +35.09% |
| Earnings growth (next 5 years) | +44.85% |
| Revenue growth (last year) | +22.88% |
| P/E ratio | NM |
| Price/Sales | 27.88 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| HZNPHorizon Therapeutics... | -0.48 | -0.48% |
| ESAIYEisai Co Ltd | +0.65 | +3.96% |
| ---- | ||
| INCYIncyte Corp | +1.01 | +1.64% |
Data as of 4:00pm ET, 06/02/2023
Financials
| Next reporting date | August 1, 2023 |
| EPS forecast (this quarter) | -$1.51 |
| Annual revenue (last year) | $1.0B |
| Annual profit (last year) | -$1.1B |
| Net profit margin | -109.04% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
